Roy de Souza

Company: BreakBio

Job title: Co-Founder & Chief Executive Officer

Seminars:

Leveraging Immunopeptidomics to Validate Endogenous Antigen Presentation & De-Risk Epitope Selection 9:00 am

• Using mass spectrometry-based immunopeptidomics to directly identify MHC-bound peptides from tumor tissue to confirm which predicted antigens are truly presented • Detecting post-translationally modified, cryptic, or low-abundance peptides that escape standard analysis to overcome predictive blind spots • Incorporating immunopeptidomics into early discovery workflows to de-risk antigen selection, reduce false positives, and support regulatory…Read more

day: Conference Day One